These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26540119)

  • 1. Prostaglandin-Associated Enophthalmos: An Observer-Masked Radiological Study of Patients Treated with Prostaglandin Drops to One Eye Only.
    Joganathan V; Aboelmagd SM; Eke T
    Orbit; 2015; 34(6):336-7. PubMed ID: 26540119
    [No Abstract]   [Full Text] [Related]  

  • 2. Unilateral Prostaglandin-Associated Periorbitopathy: A Syndrome Involving Upper Eyelid Retraction Distinguishable From the Aging Sunken Eyelid.
    Rabinowitz MP; Katz LJ; Moster MR; Myers JS; Pro MJ; Spaeth GL; Sharma P; Stefanyszyn MA
    Ophthalmic Plast Reconstr Surg; 2015; 31(5):373-8. PubMed ID: 25393907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
    Kucukevcilioglu M; Bayer A; Uysal Y; Altinsoy HI
    Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Periocular changes following long-term administration of latanoprost 0.005%.
    Ung T; Currie ZI
    Ophthalmic Plast Reconstr Surg; 2012; 28(2):e42-4. PubMed ID: 21659917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
    Schwartz GF; Tan J; Kotak S
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Orbital fat atrophy in glaucoma patients treated with topical bimatoprost--can bimatoprost cause enophthalmos?].
    Tappeiner C; Perren B; Iliev ME; Frueh BE; Goldblum D
    Klin Monbl Augenheilkd; 2008 May; 225(5):443-5. PubMed ID: 18454393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased orbital fat and enophthalmos due to bimatoprost: Quantitative analysis using magnetic resonance imaging.
    Higashiyama T; Minamikawa T; Kakinoki M; Sawada O; Ohji M
    PLoS One; 2019; 14(3):e0214065. PubMed ID: 30917168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial.
    Arcieri ES; Santana A; Rocha FN; Guapo GL; Costa VP
    Arch Ophthalmol; 2005 Feb; 123(2):186-92. PubMed ID: 15710814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periorbital changes associated with topical bimatoprost.
    Filippopoulos T; Paula JS; Torun N; Hatton MP; Pasquale LR; Grosskreutz CL
    Ophthalmic Plast Reconstr Surg; 2008; 24(4):302-7. PubMed ID: 18645437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serious spinal sequelae following the use of eye drops.
    Park JC; Jones DH
    Eye (Lond); 2010 Jun; 24(6):1109. PubMed ID: 19876072
    [No Abstract]   [Full Text] [Related]  

  • 11. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin agonist effect on matrix metalloproteinase aqueous levels in glaucoma patients.
    Pradhan ZS; Dalvi RA; Lai T; Kranemann C; Boyd S; Birt CM
    Can J Ophthalmol; 2015 Feb; 50(1):6-10. PubMed ID: 25677276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness.
    Zhong Y; Shen X; Yu J; Tan H; Cheng Y
    Cornea; 2011 Aug; 30(8):861-4. PubMed ID: 21499083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops.
    Kozobolis VP; Detorakis ET; Maskaleris G; Koukoula SC; Fountoulakis N; Chrysochoou F; Konstas AG
    Am J Ophthalmol; 2005 Apr; 139(4):742-3. PubMed ID: 15808188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
    Li N; Chen XM; Zhou Y; Wei ML; Yao X
    Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost analysis of the prostaglandin analogs.
    Mick AB; Gonzalez S; Dunbar MT; McSoley JJ
    Optometry; 2002 Oct; 73(10):614-9. PubMed ID: 12408547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence.
    Zimmerman TJ; Hahn SR; Gelb L; Tan H; Kim EE
    J Ocul Pharmacol Ther; 2009 Apr; 25(2):145-52. PubMed ID: 19284321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of topical prostaglandin drops on angiogenesis in an in ovo chick chorioallantoic membrane model.
    Sabaner MC; Duman R; Vurmaz A; Ertekin T
    Cutan Ocul Toxicol; 2021 Mar; 40(1):54-60. PubMed ID: 33461354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update in glaucoma: the new pharmacotherapies. Latanoprost.
    Buys YM
    Can J Ophthalmol; 1998 Aug; 33(5):255-7; discussion 257-8. PubMed ID: 9740953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.